BioNTech (BNTX / 22UA GY) and co-founders announce plan to pursue next-gen mRNA innovations in co-founders-led new Co.

The announcement from BioNTech regarding the formation of a new company led by its co-founders to pursue next-generation mRNA innovations indicates a strategic pivot that could enhance their competitive edge in the biotech sector.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Iran notes an explosion of an oil tanker near Abu Dhabi, according to Iranian Press

UK Court has refused permission for a legal challenge after UK-Mauritius deal on Chagos Islands

BioNTech (BNTX / 22UA GY) and co-founders announce plan to pursue next-gen mRNA innovations in co-founders-led new Co.

NIO Inc. (NIO) Q4 2025 (CNY): EPS -- (exp. -0.06), Revenue 34.7bln (exp. 37.29bln)

Germany sells EUR 3.871bln vs exp. EUR 5bln 2.10% 2028 Schatz: b/c 1.61x (prev. 1.77x), average yield 2.72% (prev. 2.02%), retention 22.6% (prev. 23.5%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move may not only bolster BioNTech's research pipeline but also spark interest among investors in biotech equities, particularly given the ongoing focus on mRNA technology since the COVID-19 vaccine's success. Key questions remain around the potential market impact and whether this will lead to further consolidation or partnerships within the industry.

Related headlines

The whole workspace, free to try.

Try it free